Pemetrexed 25mg/ml Concentrate for Solution for Infusion (Caduceus Pharma Ltd)

Country: United Kingdom

Language: English

Source: myHealthbox

Active ingredient:

pemetrexed

Available from:

Caduceus Pharma Ltd.

ATC code:

L01BA04

INN (International Name):

pemetrexed

Dosage:

25mg

Pharmaceutical form:

Concentrate for solution for infusion

Administration route:

intravenous infusion

Units in package:

1 x 4 ml vial (100 mg/4 ml) 1 x 20 ml vial (500 mg/20 ml) 1 x 40 ml vial (1000 mg/ 40 ml)

Prescription type:

POM - Prescription Only Medicine

Manufactured by:

Actavis Italy

Therapeutic group:

Folic acid analogues

Therapeutic indications:

Malignant pleural mesothelioma Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

Authorization status:

Authorised

Authorization date:

2015-12-09

Patient Information leaflet

!
READ ALL OF THIS LEAFLET CAREFULLY BEFORE 
YOU START RECEIVING THIS MEDICINE 
BECAUSE IT CONTAINS IMPORTANT 
INFORMATION FOR YOU.
•  
Keep this leaflet. You may need to read 
it again.
•   If you have any further questions, ask 
your doctor, nurse or pharmacist.
•   If you get any side effects, talk to 
your doctor, nurse or pharmacist. This 
includes any possible side effects not 
listed in this leaflet. See section 4.
•   The full name of this medicine is 
Pemetrexed 25mg/ml Concentrate 
for Solution for Infusion but within 
the leaflet it will be referred to as 
Pemetrexed.
WHAT IS IN THIS LEAFLET:
1.   What Pemetrexed is and what it is 
  used for
2.   What you need to know before you use 
Pemetrexed
3.  How to use Pemetrexed
4.  Possible side effects
5.  How to store Pemetrexed
6.   Contents of the pack and other 
information
1.   WHAT PEMETREXED IS AND WHAT IT IS 
USED FOR
Pemetrexed is a medicine used in the 
treatment of cancer. It contains the active 
substance pemetrexed. Pemetrexed 
belongs to a group of medicines known 
as folic acid analogues and disrupts 
processes that are essential for cells to 
divide.
Pemetrexed is given in combination 
with cisplatin, another anti-cancer 
medicine, as treatment for malignant 
pleural mesothelioma, a form of cancer 
that affects the lining of the lung, to 
patients who have not received prior 
chemotherapy.
Pemetrexed is also given in combination 
with cisplatin for the initial treatment 
of patients with advanced stage of lung 
cancer.
Pemetrexed can be prescribed to you 
if you have lung cancer at an advanced 
stage if your disease has responded to 
treatment or it remains largely unchanged 
after initial chemotherapy.
Pemetrexed is also a treatment for 
patients with advanced stage of lung 
cancer whose disease has progressed after 
other initial chemotherapy has been used.
2.   WHAT YOU NEED TO KNOW BEFORE YOU 
USE PEMETREXED 
DO NOT USE PEMETREXED
•   if you are aller

Summary of Product characteristics

3HPHWUH[HGPJPO&RQFHQWUDWHIRU6ROXWLRQIRU,QIXVLRQ&DGXFHXV3KDUPD/WG
6XPPDU\RI3URGXFW&KDUDFWHULVWLFV8SGDWHG'HF_$FWDYLV8./WG
1DPHRIWKHPHGLFLQDOSURGXFW
3HPHWUH[HGPJPO&RQFHQWUDWHIRU6ROXWLRQIRU,QIXVLRQ
4XDOLWDWLYHDQGTXDQWLWDWLYHFRPSRVLWLRQ
2QHPORIFRQFHQWUDWHFRQWDLQVPJSHPHWUH[HGDVSHPHWUH[HGGLWURPHWDPRO
2QHYLDORIPOFRQFHQWUDWHFRQWDLQVPJSHPHWUH[HGDVSHPHWUH[HGGLWURPHWDPRO
2QHYLDORIPOFRQFHQWUDWHFRQWDLQVPJSHPHWUH[HGDVSHPHWUH[HGGLWURPHWDPRO
2QHYLDORIPOFRQFHQWUDWHFRQWDLQVPJSHPHWUH[HGDVSHPHWUH[HGGLWURPHWDPRO
)RUWKHIXOOOLVWRIH[FLSLHQWVVHHVHFWLRQ
3KDUPDFHXWLFDOIRUP
&RQFHQWUDWHIRUVROXWLRQIRULQIXVLRQ
7KHFRQFHQWUDWHLVFOHDUFRORXUOHVVWRVOLJKWO\\HOORZLVKRU\HOORZJUHHQLVKVROXWLRQ
7KHS+LVEHWZHHQDQG
&OLQLFDOSDUWLFXODUV
7KHUDSHXWLFLQGLFDWLRQV
0DOLJQDQWSOHXUDOPHVRWKHOLRPD
3HPHWUH[HGLQFRPELQDWLRQZLWKFLVSODWLQLVLQGLFDWHGIRUWKHWUHDWPHQWRIFKHPRWKHUDS\QDwYHSDWLHQWVZLWK
XQUHVHFWDEOHPDOLJQDQWSOHXUDOPHVRWKHOLRPD
1RQVPDOOFHOOOXQJFDQFHU
3HPHWUH[HGLQFRPELQDWLRQZLWKFLVSODWLQLVLQGLFDWHGIRUWKHILUVWOLQHWUHDWPHQWRISDWLHQWVZLWKORFDOO\DGYDQFHGRU
PHWDVWDWLFQRQVPDOOFHOOOXQJFDQFHURWKHUWKDQSUHGRPLQDQWO\VTXDPRXVFHOOKLVWRORJ\VHHVHFWLRQ
3HPHWUH[HGLVLQGLFDWHGDVPRQRWKHUDS\IRUWKHPDLQWHQDQFHWUHDWPHQWRIORFDOO\DGYDQFHGRUPHWDVWDWLFQRQVPDOOFHOO
OXQJFDQFHURWKHUWKDQSUHGRPLQDQWO\VTXDPRXVFHOOKLVWRORJ\LQSDWLHQWVZKRVHGLVHDVHKDVQRWSURJUHVVHG
LPPHGLDWHO\IROORZLQJSODWLQXPEDVHGFKHPRWKHUDS\VHHVHFWLRQ
3HPHWUH[HGLVLQGLFDWHGDVPRQRWKHUDS\IRUWKHVHFRQGOLQHWUHDWPHQWRISDWLHQWVZLWKORFDOO\DGYDQFHGRUPHWDVWDWLF
QRQVPDOOFHOOOXQJFDQFHURWKHUWKDQSUHGRPLQDQWO\VTXDPRXVFHOOKLVWRORJ\VHHVHFWLRQ
3RVRORJ\DQGPHWKRGRIDGPLQLVWUDWLRQ
3HPHWUH[HGPXVWRQO\EHDGPLQLVWHUHGXQGHUWKHVXSHUYLVLRQRIDSK\VLFLDQTXDOLILHGLQWKHXVHRIDQWLFDQFHU
FKHPRWKHUDS\
3RVRORJ\
_3HPHWUH[HGLQFRPELQDWLRQZLWK